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Background: Magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU) is a promising technique for
palliative treatment of bone pain. In this study, the effects of MR-HIFU ablation on bone mechanics and modeling
were investigated.
Methods: A total of 12 healthy rat femurs were ablated using 10 W for 46 ± 4 s per sonication with 4 sonications
for each femur. At 7 days after treatments, all animals underwent MR and single photon emission computed
tomography/computed tomography (SPECT/CT) imaging. Then, six animals were euthanized. At 1 month
following ablations, the remaining six animals were scanned again with MR and SPECT/CT prior to euthanization.
Thereafter, both the HIFU-treated and contralateral control bones of three animals from each time interval were
processed for histology, whereas the remaining bones were subjected to micro-CT (μCT), three-point bending
tests, and micro-finite element (micro-FE) analyses.
Results: At 7 days after HIFU ablations, edema formation around the treated bones coupled with bone marrow
and cortical bone necrosis was observed on MRI and histological images. SPECT/CT and μCT images revealed
presence of bone modeling through an increased uptake of 99mTc-MDP and formation of woven bone,
respectively. At 31 days after ablations, as illustrated by imaging and histology, healing of the treated bone and
the surrounding soft tissue was noted, marked by decreased in amount of tissue damage, formation of scar
tissue, and sub-periosteal reaction. The results of three-point bending tests showed no significant differences in
elastic stiffness, ultimate load, and yield load between the HIFU-treated and contralateral control bones at 7 days
and 1 month after treatments. Similarly, the elastic stiffness and Young’s moduli determined by micro-FE analyses
at both time intervals were not statistically different.
Conclusions: Multimodality imaging and histological data illustrated the presence of HIFU-induced bone
damage at the cellular level, which activated the bone repair mechanisms. Despite that, these changes did not
have a mechanical impact on the bone.
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High-intensity focused ultrasound (HIFU) is a non-
invasive thermal therapy, which uses acoustic energy to
locally heat the tissue to ablative temperature, thereby
leading to cell death [1, 2]. This technique is often
performed under the guidance of magnetic resonance
imaging (MR-HIFU) to aid treatment planning, enable
temperature monitoring to ensure precise heating dur-
ing treatments, and immediate follow-up assessments
thereafter. To date, MR-HIFU has been utilized in the
clinic for treatment of uterine fibroids [3–5] and is cur-
rently under investigation for treatment of prostate [6–8],
breast [9, 10], liver [11, 12], and pancreatic [13, 14]
cancers.
In the recent years, MR-HIFU has also been approved
as an alternative palliative treatment method for cancer-
induced bone pain in radiation refractory patients. This
approach was assumed to alleviate pain through periosteal
denervation. In patients with bone metastases, MR-HIFU
ablations provided pain relief in 60–100 % of the patients
[15–20]. Similarly, in patients with osteoid osteoma,
complete pain relief was observed in 90 % of the patients
from 1 month after treatments until the 12-month follow-
up period [21]. Interestingly, the palliative efficacy of
MR-HIFU ablation has been extended to treatment of
osteoarthritic pain of the facet joints [22, 23] and knee
[24]. In the knee osteoarthritic pain study, the visual
analog scale (VAS) scores of 75 % of the patients were
reduced from the third day following treatments and
the observed pain relief effects remained at 6-month
follow up [24]. In addition to pain palliation, preclinical
[25] as well as clinical [16, 18] results have shown the
prospect of HIFU-induced osteogenesis. Bucknor et al.
demonstrated that MR-HIFU ablations of healthy pig
femurs caused new bone formation at the treated sites
[25]. In clinical studies, ablation of osteolytic lesions led
to de novo mineralization of cortical bone [16, 18].
Although MR-HIFU ablation provides pain relief and
promotes skeletal remodeling, this treatment method also
induces cortical bone damage. As illustrated by different
preclinical studies using healthy bones, osteocyte necrosis
was detected in the ablated cortical bone [26–28]. There-
fore, aggressive ablation of bone may compromise bone
strength. Recently, the effects of MR-HIFU treatments on
the mechanical properties of bone were first examined by
Herman et al. in pig ribs [29]. In their study, a reduction
in bone mechanical properties was observed at 6 weeks
after HIFU treatments, but these changes reversed at
12 weeks after ablations. A drawback of their study is that
non-weight-bearing bones were used and that ribs have a
different morphology and function than long bones. As
weight-bearing bones are more at risk of pathological frac-
tures, assessing the effects of MR-HIFU on the biomech-
anical properties of weight-bearing bones is essential andwarranted [30]. Therefore, in this study, the effects of MR-
HIFU ablation on the mechanical properties of weight-
bearing bones in a rat animal model were investigated by
using three-point bending tests and micro-finite element
(micro-FE) analyses. The animal model was chosen as it
allows a full comparative study with small animal imaging,
histology, and eventually tumor-bearing bones. We chose
the time points of 7 days and 1 month for our study to re-
duce transient effects directly after HIFU treatments,
while keeping it comparable to other ablation studies in
small animals [31–34]. Subsequently, the findings were
correlated with bone damage and modeling as assessed




All animal experiments were approved by the local
animal welfare committee (Maastricht University, The
Netherlands) and conformed to the ethical guidelines
set by the institutional animal care committee. Male
Copenhagen rats with a minimum age of 12 weeks were
used (Jackson Laboratory, USA). Two experimental
groups were included in this study with n = 6 for each
group: (1) animals euthanized at 7 days after treatments
(group 1) and (2) animals euthanized 1 month after
treatments (group 2) (Fig. 1). At the beginning of the
study, all animals underwent MR-HIFU ablation on
their respective left femurs. At 7 days after treatments,
animals from group 1 were subjected to MRI and single
photon emission computed tomography/computed
tomography (SPECT/CT) prior to euthanization. There-
after, both the HIFU-treated and contralateral healthy
femurs were excised. Femurs from three animals were
processed for histological analyses, whereas the
remaining femurs were scanned using micro-CT (μCT)
for micro-FE analyses and subsequently tested in a
three-point bending apparatus (Fig. 1). The animals in
group 2 were scanned with MRI and SPECT/CT at
7 days and 1 month after treatments. Next, the animals
were euthanized, and all femurs were processed simi-
larly to the animals in group 1 (Fig. 1).
MR-HIFU ablation
Prior to HIFU ablation, the animals were given carprofen
(Rimadyl®, Pfizer Inc., New York, USA) at 4 mg/kg body
weight to relieve treatment-related pain. Then, the limb
subjected to treatment was shaved and covered with de-
gassed ultrasound gel (Aquasonic 100, Parker Laboratories,
Fairfield, USA). Subsequently, the limb was submerged in
degassed water and positioned in a multichannel small
animal MR receiver coil to enable usage with a clinical
3-T MR-HIFU platform (Philips Sonalleve®, Vantaa,
Finland). T1-weighted fast field echo (FFE, repetition
Fig. 1 Experimental groups and their respective experimental timelines
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view (FOV) = 100 × 70 × 71 mm3, voxel size = 0.5 × 0.5 ×
1.0 mm3, number of signal averages (NSA) = 4) and T2-
weighted turbo spin echo (TSE, TR = 20,752 ms, TE =
43 ms, FOV = 100 × 70 × 71 mm3, voxel size = 0.5 × 0.5 ×
1.0 mm3, NSA = 2) sequences were acquired for treatment
planning. Four treatment cells (2 × 2 × 7 mm3) were posi-
tioned behind the bone and along the femoral shaft
(Fig. 2). Several sub-therapeutic sonications (acoustic fre-
quency = 1.44 MHz, acoustic power = 5 W, duration =
20 s per sonication, continuous wave ultrasound) were
performed to ensure temperature increase in the planned
treatment sites. HIFU ablation was performed using 10 W
acoustic power for 46 ± 4 s. During the treatment, MR
thermometry sequences (RF-spoiled gradient with echo
planar imaging (EPI) readout, EPI factor = 7, TR = 38 ms,
TE = 20 ms, FOV= 250 × 250 mm2, voxel size = 1.4 × 1.4 ×
4.0 mm3, SENSE factor = 1.8, fat suppression = spectral pre-
saturation with inversion recovery (SPIR), NSA = 2, dy-
namic scan time = 4.8 s) were acquired using one sliceFig. 2 Representative T1-weighted image for position of treatment cells for
Treatment cells (A)parallel and three slices perpendicular to the ultrasound
beam. Following ablation, a gadolinium-based contrast
agent (Dotarem®, Guerbet LLC, Bloomington, USA) was
injected at 0.2 mmol/kg body weight and contrast-
enhanced (CE)-MR images were acquired using a T1-
weighted FFE sequence for assessment of non-perfused re-
gions. T2-weighted images were acquired for assessment of
edema.
Multimodality imaging assessments of MR-HIFU ablation
MRI
The soft tissue changes due to MR-HIFU ablation were
assessed using MR images taken with a whole body
SENSE rat coil (Rapid Biomedical, Germany) and a 3-T
MRI scanner (Philips Healthcare, The Netherlands). T2-
weighted MR images were acquired using a TSE se-
quence (TR = 8724 ms, TE = 28 ms, FOV = 70 × 70 ×
25 mm3, voxel size = 0.35 × 0.35 × 0.70 mm3, NSA = 4)
for evaluation of edema. T1-weighted FFE (TR = 20 ms,
TE = 5.3 ms, FOV = 70 × 70 × 25 mm3, voxel size = 0.35 ×MR-HIFU ablation. Direction of ultrasound beam (white arrow).
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and after injection of DOTAREM® at 0.2 mmol/kg body
weight to assess tissue damage.
SPECT/CT
The area with high bone turnover following HIFU treat-
ments was investigated using a high resolution small ani-
mal SPECT/CT scanner (NanoSPECT/CT®, Bioscan,
USA) equipped with four detector heads and converging
9-pinhole collimators (pinhole diameter = 2.5 mm) in
combination with 99mTc-MDP. 99mTc-MDP was injected
at 76 ± 3 MBq. The CT of both femurs was acquired
with 360 projections, 2-s exposure time per projection
and a peak tube voltage of 65 kV, to provide anatomical
reference. At 2 h after injection, SPECT images of both
femurs were acquired with 32 projections and 200 s per
projection. SPECT and CT images were reconstructed,
and qualitative assessments of the SPECT images were
done using InVivoScope software (Bioscan).
μCT
The bone micro-architecture of the treated and contra-
lateral femur was acquired using a vivaCT 40 scanner
(Scanco Medical AG, Switzerland). μCT images of the
whole femur were acquired with a voxel size of 25 μm
(45 kVp, 175 μA, 500 projections per 180°, 300-ms inte-
gration time).
Three-point bending tests
A destructive three-point bending test was performed on
both the HIFU-treated and contralateral control femurs
(Universal testing machine Z 010/TN2S, Zwick, Ulm,
Germany) to determine their elastic stiffness, ultimate
load, and yield load, defined as the force at the changing
point between the elastic and plastic ranges. The femurs
were supported at the distal and proximal ends as
depicted in Fig. 3a. Then, a load was applied in the mid-
femoral shaft up to failure at a speed of 0.1 mm/min.
The experimental bone elastic stiffness was defined asFig. 3 Three-point bending test. a The femurs were supported at the dista
the mid-femoral shafts. b A representative load-displacement graph. Linearthe slope of the linear elastic range from the obtained
load-displacement graph (Fig. 3b). The changes in mech-
anical properties due to HIFU treatments were obtained
by comparing results for the treated femurs with those
of their respective contralateral control femurs at both
time intervals. The time-dependent change in mechan-
ical properties due to HIFU treatments was obtained by
comparing the ratios of the HIFU-treated divided by the
contralateral control bones at 7 days and 1 month post
treatments.
Micro-FE analyses of bone biomechanical properties
The μCT scans were rotated in such a way that their
orientation corresponded to that in the three-point
bending experiments. In order to reduce the total num-
ber of elements for the micro-FE analyses, the image
resolution was reduced to 50 μm. Thereafter, images
were thresholded using a single threshold of 500 per
mille of the maximum possible value to segment solely
the normally mineralized bone tissue. Then, the images
were cropped to include only the region between the
bottom rollers plus 0.5 mm on each side. The images
were converted to micro-FE models using a voxel con-
version technique [35]. Linear elastic material properties
were assigned to all materials with a Young’s modulus of
10 GPa for the bone elements while the Poisson’s ratio
was set to 0.3. Boundary conditions were chosen to rep-
resent the rollers’ support conditions at the bottom while
a vertical displacement was prescribed at the location
where the top roller was in contact with the bone. The
bone stiffness was defined similarly to the three-point
bending experiment. Finally, the ratio of the experimen-
tally determined stiffness and the micro-FE-calculated
stiffness was determined. After multiplying this ratio
with the bone tissue value of 10 GPa prescribed in the
micro-FE models, the actual tissue modulus can be back
calculated [35]. All image processing and micro-FE sim-
ulations were done using IPL v5.16 (Scanco Medical AG,
Brüttisellen, Switzerland).l and proximal ends by two rolling pins while a load was applied in
elastic range (red dashed line) and plastic range (blue dashed line)
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The femurs were decalcified in 12.5 % ethylenediamine-
tetraacetic acid pH 7.4 solutions. Next, samples were
processed for paraffin embedding. The femurs were sec-
tioned at a 4-μm thickness using a microtome. Subse-
quently, the samples were machine-stained (ArtisanTM
Link Pro, Dako, Belgium) with hematoxylin and eosin
(H&E). Histological images were acquired at 20× magni-
fication (ScanScope XT, Aperio, USA).
Statistical analyses
The Wilcoxon signed rank test was used for all paired
comparisons of the HIFU-treated versus the contralat-
eral control bones in the three-point bending tests and
micro-FE analyses. The two-sided t test was used to
compare if the bone mechanical properties (elasticFig. 4 Multimodality imaging of MR-HIFU ablation. a–c T2-weighted MRI of
Edema was observed around the treated bone while mixed hypo- and hyp
Yellow arrows show lines with hypo-intense signal, which are similar to cor
(d–f) and after (g–i) contrast agent injections. h Non-perfused region was o
Hypo-intense region in the intramedullary space suggest bone marrow dam
1 month (l) after HIFU ablation. k–l Areas with increased 99mTc-MDP accum
and on the cortical surface. m–o μCT images of femurs before (m) and afte
observed in the intramedullary space at 7 days and 1 month post treatmen
after treatmentsstiffness, ultimate load, yield load, and Young’s modulus)
changed from 7 days to 1 month due to HIFU treat-
ments, to investigate the changes in mechanical proper-
ties of bones due to growth from 7 days to 1 month, and
to evaluate the differences in stiffness obtained from the
three-point bending tests and micro-FE analyses. Ana-
lyses were performed using SPSS Statistics (v22, IBM,
USA). Data are presented as the mean ± standard devi-
ation (sd), with P < 0.05 considered significant.
Results
Multimodality imaging of MR-HIFU ablation
At 7 days after MR-HIFU ablation, treatment-associated
edema, a region with hyper-intense signal around the
bone compared to control in T2-weighted MR images,
was observed (Fig. 4a, b). Within the intramedullaryfemurs before (a), at 7 days (b), and at 1 month (c) after ablations. b
er-intense signal was present in the intramedullary space. b–c, f, i
tical bone, in the intramedullary space. d–i T1-weighted MRI prior to
bserved around the treated bone after contrast agent administration. i
age. j–l SPECT/CT images before (j) and at 7 days (k) as well as
ulation (yellow arrows) were detected within the intramedullary space
r (n–o) HIFU ablation. n–o Woven bone formation (yellow arrow) was
ts. o Cortical thickening (white arrows) was present at 1 month
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tical bone were found to flank the borders of the edema,
while mixed hypo- and hyper-intense signals were present
in the intramedullary space suggesting bone marrow
damage (Fig. 4b). The corresponding T1-weighted MR im-
ages after injection of DOTAREM® showed comparable
non-perfused region, marked by hypo-intense signal
(Fig. 4d, e, g, h). SPECT/CT images at the same time point
showed increased uptake of 99mTc-MDP in the intrame-
dullary space and on the surface of the cortical bone
(Fig. 4j, k). These hotspots were also located at the periph-
ery of the ablation zones. In line with MR and SPECT/CT
images, woven bone formation was detected within the
intramedullary space of the μCT images (Fig. 4m, n).
At 1 month after MR-HIFU ablation, edema around
the treated femurs had resolved (Fig. 4c). Interestingly,
the two lines with hypo-intense signal still remained, but
the distance between these lines had shrunk from 18.6
to 12.6 mm (Fig. 4b, c). The T1-weighted images showed
comparable hypo-intense signal lines within the bone
marrow (Fig. 4f, i). Following injection of contrast
agents, the non-perfused region in the surroundingFig. 5 Mechanical properties of the HIFU-treated and contralateral control
three-point bending tests. a Elastic stiffness. b Ultimate load. c Yield load. *tissue had diminished (Fig. 4i). The intramedullary space
showed regions of hypo-intense signal, indicating bone
marrow damage (Fig. 4i). In addition, similar to MR im-
ages, the distance between the HIFU-induced hotspots
in SPECT/CT images had decreased from 19.3 to
13.9 mm, confirming progression of bone modeling
(Fig. 4k, l). Moreover, increased uptake of 99mTc-MDP
was observed on the cortical bone surface. As expected,
visual inspection of the μCT images confirmed the pres-
ence of woven bone formation and cortical thickening
(Fig. 4o).
Three-point bending test
The average elastic stiffness, ultimate load, and yield
load of the HIFU-treated and contralateral control bones
at both time intervals after ablations are shown in Fig. 5.
At 7 days, the stiffness, ultimate load, and yield load
were 6 ± 15 %, 6 ± 6 % and 16 ± 5 % less than those of
the control bones, respectively. However, no significant
differences were found between the treated and control
bones [P = 0.29 (stiffness, ultimate load), 0.11 (yield
load)]. Due to growth of the animals at 1-month timebones at 7 days and 1 month after treatments determined by
P < 0.05
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trol bones were significantly higher (P < 0.05). At this
time point, the stiffness of the treated bone was 13 ±
16 % higher than that of the control ones, whereas the
yield and ultimate loads were 8 ± 5 % and 8 ± 4 % less,
respectively. Similarly, no significant differences between
the treated and control bones were noted [P = 0.29 (stiff-
ness), 0.11 (ultimate load, yield load)]. From 7 days to
1 month, by comparing the ratio of the HIFU-treated di-
vided by control bone, no significant changes in elastic
stiffness (P = 0.60), ultimate load (P = 0.12), and yield
load (P = 0.09) due to HIFU treatments were observed.
Micro-FE analyses
The stiffness values measured in the three-point bending
tests (Fig. 5) for the two time intervals were in good
agreement with the predictions of the micro-FE analyses
(Fig. 6). For the micro-FE calculated stiffness, no signifi-
cant differences were found between the treated and
control bones at 7 days (P = 0.59) and 1 month (P = 0.29)
after treatments. In addition, there was a significant in-
crease in stiffness over time due to the growth (P < 0.05).
The calculation of the tissue Young’s moduli by com-
paring the experimental and micro-FE results revealed
no significant differences between the treated and con-
trol bones at 7 days (P = 0.59) and 1 month (P = 0.11).
Likewise, by comparing the ratio of the HIFU-treated
divided by control bone, no significant differences due
to HIFU treatments were found between the two time
intervals for elastic stiffness (P = 0.49) and Young’s
moduli (P = 0.22).
Histological analyses
At 7 days after MR-HIFU treatments, ablation of bones
and the surrounding soft tissue was observed (Fig. 7a).
Within the ablation zone, osteonecrosis of the cortical
bone, marked by empty lacunae, was noted (Fig. 7b). In
line with the heterogeneous hypo- and hyper-intense sig-
nal in T2-weighted MR image at 7 days post ablation
(Fig. 4b), the intramedullary space exhibited a mixture ofFig. 6 Mechanical properties of the HIFU-treated and contralateral control
analyses. a Elastic stiffness. b Young’s modulus. *P < 0.05viable and non-viable bone marrow (Fig. 7c). At the bor-
ders of the ablated zone, woven bone formation was ob-
served in the intramedullary space (Fig. 7d). Moreover,
at the same locations, a sharp demarcation between the
ablated and viable osteocytes was detected (Fig. 7e).
Sub-periosteal woven bone formation was also present
at the periphery of the ablated area (Fig. 7f ).
At 1 month after MR-HIFU treatments, the surround-
ing soft tissue had started healing leading to a smaller
area of soft tissue damage, which was in line with the
MR images (Figs. 4 and 7g), while the cortical bone
remained necrotic (Fig. 7h). A part of the necrotic mar-
row had been replaced by an immature collagenous
matrix made up of fibrovascular structures, an indication
of bone marrow repair (Fig. 7i). Similar to the 7-day
time point, woven bone was present in the intramedul-
lary space (Fig. 7j). Consistent with the imaging results
(Fig. 4), the distance between the woven bones in the
intramedullary space had decreased (Fig. 7g). Although
the woven bone in the intramedullary space had moved
inward to allow for the return of the viable marrow cells,
the adjacent cortical bone remained necrotic (Fig. 7k),
suggesting a faster bone marrow healing process com-
pared to the cortical bone. In agreement with the μCT
results (Fig. 4o), the woven bone on the periosteal sur-
face was more calcified, thereby contributing to cortical
thickening (Fig. 7l).
Discussion
Bone pain as a result of tumor growth affects 75 % of
patients with advanced cancer [36]. These patients ex-
perience not only severe pain but also reduced quality of
life. As radiation therapy (RT) is a suboptimal pain res-
cue treatment approach for localized painful lesions, de-
velopment of alternative treatments for patients who do
not respond to RT is crucial [37, 38]. MR-HIFU ablation
is a promising technique for radiation refractory pa-
tients. Through understanding the bone functional
changes and bone modeling induced by MR-HIFU, this
technique can be applied in a safer and more effectivebones at 7 days and 1 month after treatments determined by micro-FE
Fig. 7 Histological analyses of bones following MR-HIFU ablations. a Whole femur at 7 days post treatment with ablation zone delineated with
dashed lines. Ablation of the soft tissue surrounding the bone was observed. b Osteonecrosis of the cortical bone, marked by empty lacunae. c
Bone marrow showed a mixture of viable and non-viable cells. d Woven bone (WB) lying in between the necrotic (NM) and viable marrow (VM)
in the intramedullary space. e A sharp demarcation (white dashed line) between ablated and viable osteocytes (arrows) was observed at the
border of the ablated area. f Sub-periosteal woven bone formation at the edge of the ablation zone. g Whole femur at 1 month post treatment
with ablation zone delineated with dashed lines. A smaller region of soft tissue damage was observed around the bone. h Osteonecrosis of the
cortical bone, marked by empty lacunae. i Fibrovascular structures and immature collagenous matrix in intramedullary space. j Woven bone
flanked by viable marrow (VM) and fibrosis. k Necrotic cortical bone adjacent to the woven bone in the intramedullary space. l Sub-periosteal woven
bone with higher calcification, leading to thickening of the cortical bone. Scale bar = 2.5 mm (a, g), 100 μm (b, h), 150 μm (c, i), 250 μm (d–f, j–l)
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niques, three-point bending tests, micro-FE, and histo-
logical analyses, the effects of MR-HIFU ablation on
weight-bearing bone were investigated.
In this study, by means of multimodality imaging and
histological analyses, we show that MR-HIFU ablations
led to necrosis of bone marrow, cortical bone, and the sur-
rounding soft tissue at 7 days post treatments, which is inagreement with previously published results [26–28]. At
1 month after treatment, soft tissue healing was noted,
marked by a reduction in amount of soft tissue damage
surrounding the bones. Moreover, as illustrated by H&E
images, bone healing was evident through formation of
woven bone and fibrovascular structures along with an
immature collagenous matrix in the intramedullary space
at the investigated time points. These bone healing
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mechanically induced bone marrow ablation in long bones
[33, 34, 39]. With time, resorption of the woven bone will
ensue to allow re-establishment of the hematopoietic and
fat cells in the bone marrow cavity [33], a phenomenon
also present in this study. In addition, sub-periosteal reac-
tion adjacent to ablation sites, an indicator of intramem-
branous bone regeneration, was detected and resembles
the results observed by others [26, 28, 34].
Besides that, data from the three-point bending tests
show that the elastic stiffness, ultimate load, and yield
load of the HIFU-treated bones did not significantly dif-
fer from the contralateral control bones at 7 days and
1 month after treatments, which were in agreement with
previously published results on non-weight-bearing
bones [29]. As expected, between the 7 days and 1 month
time intervals, significant differences were observed in
mechanical properties, which was due to the presence of
normal growth. However, changes in mechanical proper-
ties due to MR-HIFU ablations alone were not discerned
between the investigated time intervals. By combining
the experimental and micro-FE results, the Young’s
moduli of bone tissue were obtained to examine poten-
tial changes at bone tissue level, which could be caused,
for instance, by micro-cracks or collagen damage. Since
no significant differences in the tissue Young’s moduli
were found at both time intervals following treatments,
we conclude that this is not the case. In line with
previous observations, no HIFU-induced fractures were
observed following treatments [17, 29]. One possible ex-
planation for the lack of any significant difference in bone
stiffness and strength between the treated and control
bones is the fact that necrotic bone at the investigated
time intervals has the same mechanical properties as
healthy bone. In our study, we deliberately assessed the ef-
fect of HIFU ablation using healthy bones to first under-
stand HIFU effects as long as the bone structure and
stability are not compromised by the presence of lesions.
In treatment of bone lesions, particularly those with osteo-
lytic phenotype, the effects of MR-HIFU would differ as
these tumor-bearing bones are more prone to formation
of fractures, but HIFU may also cause re-mineralization of
the lesion. Therefore, future studies should be performed
on lesion-bearing bones using the tools presented here.
Conclusions
In conclusion, using MRI, SPECT/CT, μCT, and histo-
logical analyses, we demonstrated that MR-HIFU abla-
tions induced bone damage at the cellular level, thereby
triggering bone repair and modeling. However, based on
three-point bending tests and micro-FE simulations, the
resulting cellular damage did not compromise the mech-
anical function of the bone or cause micro-cracks at the
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